Pieris Pharmaceuticals to Present Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/ONC0055 at the Society for Immunotherap...
October 02 2018 - 8:00AM
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a
clinical-stage biotechnology company advancing novel
biotherapeutics through its proprietary Anticalin® technology
platform for cancer, respiratory and other diseases, announced
today that preclinical data for PRS-344/ONC0055 will be presented
at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in
Washington, D.C. PRS-344/ONC0055 is one of currently five programs
Pieris is developing as part of its immuno-oncology collaboration
with Servier.
Presentation Details
Title: Simultaneous costimulatory T-cell
engagement and checkpoint inhibition by PRS-344/ONC0055, a 4-1BB /
PD-L1 bispecific compound for tumor localized activation of the
immune system Poster Number:
P375Date/Time: Thursday, November 9, 2018, 8
AM – 8 PM EDT and Friday, November 10, 2018, 8 AM – 8:30 PM
EDTLocation: Hall E, Walter E. Washington
Convention Center, Washington, DC
The poster will be made available on the Publications section of
the Company’s website at www.pieris.com.
About Pieris Pharmaceuticals
Pieris is a clinical-stage biotechnology company that discovers
and develops Anticalin protein-based drugs to target validated
disease pathways in a unique and transformative way. Our pipeline
includes immuno-oncology multi-specifics tailored for the tumor
microenvironment, an inhaled Anticalin protein to treat
uncontrolled asthma and a half-life-optimized Anticalin protein to
treat anemia. Proprietary to Pieris, Anticalin proteins are a novel
class of therapeutics validated in the clinic and by partnerships
with leading pharmaceutical companies. Anticalin® is a registered
trademark of Pieris. For more information, visit
www.pieris.com.
Forward Looking Statements
This press release contains forward-looking statements as that
term is defined in Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Statements in
this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, references to novel technologies and
methods and our business and product development plans, including
the advancement of our proprietary and co-development programs into
and through the clinic. Actual results could differ from those
projected in any forward-looking statements due to numerous
factors. Such factors include, among others, our ability to raise
the additional funding we will need to continue to pursue our
business and product development plans; the inherent uncertainties
associated with developing new products or technologies and
operating as a development stage company; our ability to develop,
complete clinical trials for, obtain approvals for and
commercialize any of our product candidates, including our ability
to recruit and enroll patients in our studies; our ability to
address the requests of the FDA; competition in the industry in
which we operate and market conditions. These forward-looking
statements are made as of the date of this press release, and we
assume no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those
projected in the forward-looking statements, except as required by
law. Investors should consult all of the information set forth
herein and should also refer to the risk factor disclosure set
forth in the reports and other documents we file with the SEC
available at www.sec.gov, including without limitation the
Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2017 and the Company's Quarterly Reports on Form
10-Q.
Company Contact: Allan Reine SVP & Chief
Financial Officer +1 857 444 4276 reine@pieris.com
Investor Relations Contact: Maria Kelman Director, Investor
Relations +1 857 362 9635 kelman@pieris.com
Pieris Pharmaceuticals (NASDAQ:PIRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pieris Pharmaceuticals (NASDAQ:PIRS)
Historical Stock Chart
From Apr 2023 to Apr 2024